Novartis
Strategic intent
Novartis is a global innovative medicines company focused on the development, manufacturing, and commercialization of breakthrough prescription therapies across oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic diseases.
Key market signals
- 2026-11: Novartis announced it would largely abandon the development of its experimental cardiovascular drug, pelacarsen, after a seven-year Phase III trial failed to reduce major cardiovascular events despite reducing lipoprotein(a) levels.
- 2026-11: Novartis confirmed nine cases of tumors in patients treated with its gene therapy Zolgensma since its 2019 approval, with two cases showing evidence of vector DNA integration, prompting safety scrutiny and calls for transparency from patient advocacy groups.
- 2026-10: Novartis recorded a $1.9 billion partial impairment charge on del-desiran (acquired via the Avidity Biosciences deal) after the drug missed its primary endpoint in a Phase III trial for myotonic dystrophy type 1.
- 2026-04: A coalition of 42 U.S. states filed a major antitrust lawsuit against Novartis and its former subsidiary Sandoz, alleging price-fixing on 31 generic medications.
- 2025-12: Novartis reached a voluntary agreement with the U.S. government to align with drug pricing priorities, committing to launch future medicines with comparable prices across high-income countries and utilizing direct-to-patient platforms.
Financial health
- In Q3 2026, Novartis reported net sales of $14.52 billion (up 4% in constant currency) and core operating income of $6.04 billion (up 11% in constant currency), with a core operating margin of 41.6% (source: https://www.novartis.com).
- Reported net income for Q3 2026 dropped 70% to $1.20 billion, heavily impacted by a $1.9 billion partial impairment charge on del-desiran (source: https://www.novartis.com).
- Free cash flow was $5.1 billion for Q3 2026, bringing the nine-month free cash flow to $14 billion (source: https://www.novartis.com).
Impact & compliance
Legal & risks
On August 7, 2025, the Second Circuit Court of Appeals affirmed a district court's summary judgment in favor of the Department of Health and Human Services, rejecting Novartis's constitutional challenges to the Inflation Reduction Act's Medicare drug price negotiation program.
Forensic audit
- Oct 2026: On October 28, 2026, Allarity Therapeutics entered into a settlement agreement with Novartis Pharma AG, under …
- Jul 2026: On July 21, 2026, the U.S. Court of Appeals for the District of Columbia Circuit affirmed a district court judgment …
- May 2026: On May 17, 2026, the U.S. District Court for the Eastern District of Arkansas denied Novartis's request for …
Proprietary analysis
- Log in to see
Strategic fit
AI-calculated strategic alignment score
- Log in to see
Cultural fit
Trust and integrity score
- Log in to see
Alignment dimensions
How this supplier scores against each of your strategic imperatives
- Log in to see
Full forensic analysis
Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.
Want the full analysis?
Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.